487 related articles for article (PubMed ID: 27455166)
1. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial.
Uranga A; España PP; Bilbao A; Quintana JM; Arriaga I; Intxausti M; Lobo JL; Tomás L; Camino J; Nuñez J; Capelastegui A
JAMA Intern Med; 2016 Sep; 176(9):1257-65. PubMed ID: 27455166
[TBL] [Abstract][Full Text] [Related]
2. Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia.
Uranga A; Artaraz A; Bilbao A; Quintana JM; Arriaga I; Intxausti M; Lobo JL; García JA; Camino J; España PP
BMC Pulm Med; 2020 Oct; 20(1):261. PubMed ID: 33028293
[TBL] [Abstract][Full Text] [Related]
3. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.
Bielicki JA; Stöhr W; Barratt S; Dunn D; Naufal N; Roland D; Sturgeon K; Finn A; Rodriguez-Ruiz JP; Malhotra-Kumar S; Powell C; Faust SN; Alcock AE; Hall D; Robinson G; Hawcutt DB; Lyttle MD; Gibb DM; Sharland M;
JAMA; 2021 Nov; 326(17):1713-1724. PubMed ID: 34726708
[TBL] [Abstract][Full Text] [Related]
4. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
5. Community-acquired pneumonia team decreases length of stay in hospitalized, low-risk patients with pneumonia.
Marcos PJ; Restrepo MI; Sanjuàn P; Ferreira-Gonzalez L; Verea-Hernando H
Hosp Pract (1995); 2013 Aug; 41(3):7-14. PubMed ID: 23948616
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
[TBL] [Abstract][Full Text] [Related]
7. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
[TBL] [Abstract][Full Text] [Related]
8. A multicentre stewardship initiative to decrease excessive duration of antibiotic therapy for the treatment of community-acquired pneumonia.
Foolad F; Huang AM; Nguyen CT; Colyer L; Lim M; Grieger J; Li J; Revolinski S; Mack M; Gandhi T; Wainaina JN; Eschenauer G; Patel TS; Marshall VD; Nagel J
J Antimicrob Chemother; 2018 May; 73(5):1402-1407. PubMed ID: 29462306
[TBL] [Abstract][Full Text] [Related]
9. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
[TBL] [Abstract][Full Text] [Related]
10. Individualizing duration of antibiotic therapy in community-acquired pneumonia.
Aliberti S; Ramirez J; Giuliani F; Wiemken T; Sotgiu G; Tedeschi S; Carugati M; Valenti V; Marchioni M; Camera M; Piro R; Del Forno M; Milani G; Faverio P; Richeldi L; Deotto M; Villani M; Voza A; Tobaldini E; Bernardi M; Bellone A; Bassetti M; Blasi F
Pulm Pharmacol Ther; 2017 Aug; 45():191-201. PubMed ID: 28666965
[TBL] [Abstract][Full Text] [Related]
11. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
12. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
[TBL] [Abstract][Full Text] [Related]
14. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia.
El Moussaoui R; Opmeer BC; de Borgie CA; Nieuwkerk P; Bossuyt PM; Speelman P; Prins JM
Chest; 2006 Oct; 130(4):1165-72. PubMed ID: 17035452
[TBL] [Abstract][Full Text] [Related]
15. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
Niederman MS; Chang JR; Stewart J; Asche CV; Lavin B; Nusrat R; Sullivan SD
Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
[TBL] [Abstract][Full Text] [Related]
16. Prescription of antibiotics for adults hospitalized with community-acquired pneumonia in Korea in 2004: a population-based descriptive study.
Yoon YK; Kim EJ; Chun BC; Eom JS; Park DW; Sohn JW; Kim MJ
Respirology; 2012 Jan; 17(1):172-9. PubMed ID: 21995414
[TBL] [Abstract][Full Text] [Related]
17. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.
Christ-Crain M; Stolz D; Bingisser R; Müller C; Miedinger D; Huber PR; Zimmerli W; Harbarth S; Tamm M; Müller B
Am J Respir Crit Care Med; 2006 Jul; 174(1):84-93. PubMed ID: 16603606
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study.
el Moussaoui R; de Borgie CA; van den Broek P; Hustinx WN; Bresser P; van den Berk GE; Poley JW; van den Berg B; Krouwels FH; Bonten MJ; Weenink C; Bossuyt PM; Speelman P; Opmeer BC; Prins JM
BMJ; 2006 Jun; 332(7554):1355. PubMed ID: 16763247
[TBL] [Abstract][Full Text] [Related]
19. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule.
Kanwar M; Brar N; Khatib R; Fakih MG
Chest; 2007 Jun; 131(6):1865-9. PubMed ID: 17400668
[TBL] [Abstract][Full Text] [Related]
20. Impact of Procalcitonin Guidance with an Educational Program on Management of Adults Hospitalized with Pneumonia.
Walsh TL; DiSilvio BE; Hammer C; Beg M; Vishwanathan S; Speredelozzi D; Moffa MA; Hu K; Abdulmassih R; Makadia JT; Sandhu R; Naddour M; Chan-Tompkins NH; Trienski TL; Watson C; Obringer TJ; Kuzyck J; Bremmer DN
Am J Med; 2018 Feb; 131(2):201.e1-201.e8. PubMed ID: 28947168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
